Unlike conventional methods, which apply NFC tags via adhesive or assembly to external elements such as labels, Linxens and Clayens have chosen to innovate by integrating the NFC tag directly into the polymer matrix of the medical device. This approach allows for the tag to be inseparably fused with the product, offering unprecedented security through an unfalsifiable Unique Identifier (UiD).
At the heart of this initiative is the development of a revolutionary mini-tag, directly moulded into the polymer of the medical device. This circular tag combines durability and discretion through the use of a flexible polymer substrate enriched with copper loops and an integrated chip.
The encapsulation process, which involves a double overmoulding (first the overmoulding of the tag, and then the overmoulding of the new insert), ensures resistance to moisture, heat, and chemicals, offering unmatched reliability for demanding medical environments.
Critical information, such as expiration date, lot number, and dosage information, is programmed onto the NFC tag immediately after moulding. This crucial step takes place during the industrialisation process, using a specialised NFC writing device that ensures constant traceability and increased security against counterfeiting and unauthorised removal.
The mini-tag strictly complies with regulatory standards for medical devices and syringes, including the European Directive on Counterfeit Medicines, ensuring complete compatibility with existing inventory or tracking systems.
"Linxens, a historical leader in micro-connectivity technologies, is positioning itself strongly in the health sector, bringing technology and expertise that find their full meaning in this context," said Yvan Malépart, SVP Healthcare & Smartcard at Linxens. "Global health challenges demand the convergence of technical and clinical expertise, with a growing need for remote monitoring, secure connections, data quality, in an aging population, increasing patient autonomy, and overburdened healthcare services. By partnering with Clayens, Linxens is committed to addressing the demands of a constantly evolving market and a dynamic innovation landscape. With this revolutionary mini-tag, Linxens offers a solution that embraces cutting-edge technological advancements, ensuring reliability, enhanced security, and unmatched traceability in the administration of treatments."
"Working with Linxens on the integration of this mini-tag marks a significant step towards safer and more traceable medical devices," said Matthieu Besse, R&D Manager at Clayens. "This collaboration is a tangible example of our ability to integrate advanced technological innovations directly into our products, while maintaining our commitment to quality and security."
Linxens and Clayens collaborate to develop a Mini NFC Tag
In a significant advance for the medical sector, Linxens, a pioneer in the design and manufacturing of electronic components, is collaborating with Clayens, a European leader in the transformation of polymers, composites, and precision metal parts, to develop a unique medical tracker directly integrated into the material
You may also like
Manufacturing
Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025
Read moreThe company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Trending Articles
You may also like
Manufacturing
Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025
The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical
Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit
As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia
AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026